Cartalax is a peptide bioregulator that is marketed for cartilage repair and joint support.
It was developed in Russia and is part of a group of short peptide “cytomedines” researched at the St. Petersburg Institute of Bioregulation and Gerontology.
⸻
What Cartalax Is Supposed to Do
Cartalax is derived from cartilage tissue and is claimed to:
Support Cartilage Regeneration
It is believed to:
•Stimulate chondrocytes (cartilage-producing cells)
•Improve collagen synthesis in joints
•Help restore damaged cartilage tissue
This is why it’s marketed for:
•Osteoarthritis
•Joint degeneration
•Athletic wear-and-tear
⸻
Reduce Joint Inflammation
Some research suggests it may:
•Reduce inflammatory signaling in joint tissue
•Improve joint mobility
However, data is mostly from Russian studies and not large Western clinical trials.
⸻
Slow Degenerative Changes
It’s promoted as a “bioregulator,” meaning it may:
•Influence gene expression in cartilage cells
•Help normalize cartilage metabolism
This theory is based on small peptide fragments acting as cellular signaling molecules.
Cartalax is marketed to:
Help repair and protect cartilage in joints, potentially improving mobility and slowing joint degeneration.